Donor Specific Transfusion 24 Hours Prior to(-24h DST) Living Donor Renal Transplantation.
- Author:
Sun Dong JUNG
1
;
Kun Tae KIM
;
Yong Hwan LEE
;
Mi Hwa JANG
;
Ji Hyun LEE
;
Dae Young KIM
;
Kyung Won KIM
;
Jin Min KONG
Author Information
1. Department of Internal Medicine, Maryknoll Hospital, Pusan, Korea.
- Publication Type:Original Article
- Keywords:
Donor specific transfusion;
Kidney transplantation;
Living donor
- MeSH:
Allografts;
Animals;
Cyclosporine;
Follow-Up Studies;
Graft Survival;
Humans;
Immune Tolerance;
Immunosuppression;
Immunosuppressive Agents;
Kidney;
Kidney Transplantation*;
Living Donors*;
Muromonab-CD3;
Organ Transplantation;
Prednisolone;
Tissue Donors*;
Transplants
- From:Korean Journal of Nephrology
1999;18(1):175-181
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The goal of the immunologic maneuvering for organ transplantation may be the donor specific immune tolerance rather than non-specific immunosuppression. Although DST is one of the most extensively studied methods for donor specific immune hyporesponsiveness, it is not widely used in recent years because of possible sensitization and overall improvement of graft survival without DST. Several human and animal studies showed that -24h DST with concomitant cyclosporine administration improved graft survival. -24 DST may not induce adverse sensitization that preclude subsequent transplantation and the procedure is simple and does not delay the operation in living donor transplantation. Between Feb. 1994 and Jan. 1997, 33 patients received 100-200ml of fresh whole blood from the kidney donor 1 day before transplantation. Twenty donors were living related and 13 donors were non- related. Mean age was 40(22-52). Two patients was diabetic. All but one received primary allograft. Cyclosporine and prednisolone were the primary immunosuppressants that started 2-3 days before transplantation. Acute rejection occurred in 11 recipients(33.3%). Acute rejection tended to occur earlier. Eight of 11 first episodes were within 3 days post- transplant, which were all recovered by either steroid pulse or OKT3. Mean follow up was 35 months. Two patients died with functioning graft. Three-year graft survival rate was 93.9%. There was no immunologic graft loss. We conclude that -24h DST may be a valuable option of immune modulation for renal transplantation with no demonstrable adverse reaction. It's beneficial effect needs to be confirmed by a larger controlled study.
